Topic 44

sars cov antiviral covid drug 19 drugs approved coronavirus replication viral pandemic inhibitors compounds protease against fda virus mpro potent inhibitor repurposing treatment effective respiratory 2019 infection microbiology inhibit vitro remdesivir anti vero clinical severe activity toxicology pharmacology ic50 syndrome candidates main treat screening ec50 acute urgent active therapeutics target inhibits efficacy potential e6 disease therapeutic caused inhibition antivirals trials inhibited promising screened library compound currently assay targeting coronaviruses hydroxychloroquine infected safety therapies design screen 3clpro agents identified worldwide crystal treatments no repurposed entry chloroquine polymerase inhibiting activities molecules assays report urgently discovery concentrations broad cytopathic molecule dose health site

264 items. Top items listed below.

Structure of Mpro from COVID-19 virus and discovery of its inhibitors 44 1

Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. 44 1

Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro 44 1

Multidrug treatment with nelfinavir and cepharanthine against COVID-19 44 1

Development of a fluorescence based, high-throughput SARS-CoV-2 3CLpro reporter assay 44 1

TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets 44 1

Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase 44 1

Conserved interactions required for in vitro inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 44 1

Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 44 1

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. 44 1

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs 44 1

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate 44 1

Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases 44 1

Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19 36 1

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication 44 1

Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic 44 1

Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction 36 1

Comparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models 44 1

Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo 44 1

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease 44 1

Substrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging 44 1

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro 44 1

Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening 44 1

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro 44 1

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs 44 1

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening 44 1

Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2 44 1

Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro 44 36 1

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity 44 1

Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376 44 1

Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2. 36 1

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing 44 1

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication 44 1

FDA approved calcium channel blockers inhibit SARS-CoV-2 infectivity in epithelial lung cells 44 1

Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV-2 Coronavirus 44 1

A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2 44 1

Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza 44 1

Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2 44 1

Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease 44 1

Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19 44 1

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors 44 1

The Effect Of Famotidine On SARS-CoV-2 Proteases And Virus Replication 44 1

Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir 44 1

The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. 44 1

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease. 44 1

Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PLpro and Mpro in in vitro studies 44 1

A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals 44 1

Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2 44 1

Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin 44 1

Nitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model 44 1

Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine 44 1

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators 44 1

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2 44 1

Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro 44 1

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells 44 1

Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2 44 1

Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication 44 1

Discovery of potent inhibitors of PLproCoV2 by screening libraries of selenium-containing compounds 44 1

Analysis of Infected Host Gene Expression Reveals Repurposed Drug Candidates and Time-Dependent Host Response Dynamics for COVID-19 44 1

Lopinavir-ritonavir is not an effective inhibitor of the main protease activity of SARS-CoV-2 in vitro 44 1

The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections 44 1

Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection 103 44 1

Resveratrol And Pterostilbene Potently Inhibit SARS-CoV-2 Infection In Vitro 44 1

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production 44 1

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities 44 7 1

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 44 1

Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid 103 44 1

Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide 73 36 1

A dynamic regulatory interface on SARS-CoV-2 RNA polymerase 44 1

Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir 161 44 1

In Vitro Inhibition of SARS-CoV-2 Infection by Bovine Lactoferrin 44 1

Structural basis for repurposing a 100-years-old drug suramin for treating COVID-19 44 1

Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle 44 1

Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing 44 1

A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 44 1

Identification of TMEM106B as proviral host factor for SARS-CoV-2 73 1

Generation of tonsil organoids as an ex vivo model for SARS-CoV-2 infection 103 73 44 1

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease 44 1

Rapid assessment of ligand binding to the SARS-CoV-2 main protease by saturation transfer difference NMR spectroscopy 44 1

SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2 44 1

Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 44 1

The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2 44 1

Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2 44 1

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine 44 1

Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids 73 44 1

Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir 44 1

AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2 44 1

Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2 44 1

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19 44 1

Rescue of SARS-CoV-2 from a single bacterial artificial chromosome 103 44 1

Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection 44 1

Repurposing low-molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2 44 1

Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro 44 1

Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19 44 1

In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2 44 1

GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition 44 1

Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza 103 1

Ebselen as a highly active inhibitor of PLProCoV2 44 1

Astodrimer sodium, dendrimer antiviral, inhibits replication of SARS-CoV-2 in vitro 44 1

Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds 73 44 1